Characterising the 2023 chikungunya outbreak in Paraguay and the potential impact of a vaccine campaign

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors would like to acknowledge funding from Coalition for Epidemic Preparedness Innovations (CEPI) and the European Research Council (grant number 804744).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The seroprevalence study was conducted as part of the Paraguay Ministry of Health Public Health Emergency Response and, therefore, did not require ethical approval. The seroprevalence study has not been published (either in full or in part) elsewhere. Following a standard operating process, the "Centro Nacional de Servicios de Sangre" (CENSSA), with the signed authorisation of the responsible Director, provided all the donated blood samples in this study. All blood samples were collected anonymously, with no identifiers that could link the sample to the original patient; there was no enrolment procedure, and the patient consent form was the standard used by the "Centro Nacional de Servicios de Sangre" (CENSSA). The biochemical analyses were conducted at the Central Public Health Laboratory of the Ministry of Health in Paraguay. The use of epidemiological surveillance data was authorised by the signature of the Director of the DGVS (Direccion General de Vigilancia de la Salud). The mathematical modelling work was conducted on aggregate data and, therefore, did not constitute personally identifiable information.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes